Attenua is a clinical-stage biopharmaceutical company developing novel, non-narcotic medicines for the treatment of chronic cough. Michael Kitt, a leading cough clinician, has joined the company as CEO. He led the development of Afferent Pharmaceutical’s cough compound which led to Merck’s $1.25 billion acquisition of the company. Chronic cough is a significant unmet medical need affecting about 2.5 million people in the US alone. No therapies are approved for this indication.

LocationMountain View, California
CEOMichael Kitt
PartnerKurt von Emster
Websitewww.attenua.com